Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-106789
Filing Date
2025-11-05
Accepted
2025-11-05 10:31:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 14503
2 EXHIBIT 99.1 tm2530303d1_ex99-1.htm EX-99.1 8541
  Complete submission text file 0001104659-25-106789.txt   24790
Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Subject) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93208 | Film No.: 251452367
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 601 CALIFORNIA STREET, SUITE 1210 SAN FRANCISCO CA 94108
Business Address 601 CALIFORNIA STREET, SUITE 1210 SAN FRANCISCO CA 94108 (415) 249-1280
Coastlands Capital LP (Filed by) CIK: 0002068530 (see all company filings)

EIN.: 333553930 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G